A roundup of exits, including IPOs and acquisitions, across the tech transfer ecosystem.

Adaptate Biotherapeutics, a UK-based antibody-based therapeutics developer focused on oncology, has agreed to an acquisition by pharmaceutical firm Takeda for an undisclosed sum. Adaptate was spun out of GammaDelta Therapeutics, itself immunotherapy developer based on research at King’s College London and the Francis Crick Institute. Both Adaptate and GammaDelta also received support from charity Cancer…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.

Thierry Heles

Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).